Literature DB >> 9873025

A discrete three-amino acid segment (LVI) at the C-terminal end of kinase-impaired ErbB3 is required for transactivation of ErbB2.

G Schaefer1, R W Akita, M X Sliwkowski.   

Abstract

ErbB3 is unique among other members of the receptor tyrosine kinase family of growth factor receptors in that its kinase domain is enzymatically impaired. This renders it incapable of transducing a signal in response to ligand binding. However, in conjunction with ErbB2, ErbB3 is a potent mediator of signaling by the growth factor heregulin. Heregulin binding to ErbB3 induces formation of a heterodimeric complex with ErbB2, and this results in transactivation of the ErbB2 kinase. Although interaction between the extracellular domains of these receptors is an essential part of this process, it was not clear whether interaction between the cytoplasmic domains is also necessary for transactivation. By examining the abilities of a series of cytoplasmic domain mutants of ErbB3 to activate ErbB2, we have found a discrete sequence of three amino acid residues (LVI), located at the carboxyl-terminal end of the impaired ErbB3 kinase region, that is obligatory for transactivation. We conclude that formation of a functional ErbB2-ErbB3 signaling complex requires the presence of a specific structural feature within the ErbB3 cytoplasmic domain and suggest that ErbB2 transactivation results from a physical interaction between the cytoplasmic domains of these receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9873025     DOI: 10.1074/jbc.274.2.859

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Stimulated ErbB4 internalization is necessary for neuregulin signaling in neurons.

Authors:  Yu Liu; Yan-Mei Tao; Ran-Sook Woo; Wen-Cheng Xiong; Lin Mei
Journal:  Biochem Biophys Res Commun       Date:  2007-01-10       Impact factor: 3.575

2.  IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance.

Authors:  Colin D White; Zhigang Li; Deborah A Dillon; David B Sacks
Journal:  J Biol Chem       Date:  2011-07-01       Impact factor: 5.157

Review 3.  The biology of human epidermal growth factor receptor 2.

Authors:  S Sundaresan; E Penuel; M X Sliwkowski
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

4.  Transmembrane peptides as inhibitors of ErbB receptor signaling.

Authors:  Amar Bennasroune; Maria Fickova; Anne Gardin; Sylvie Dirrig-Grosch; Dominique Aunis; Gérard Crémel; Pierre Hubert
Journal:  Mol Biol Cell       Date:  2004-05-14       Impact factor: 4.138

Review 5.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

6.  Co-conserved features associated with cis regulation of ErbB tyrosine kinases.

Authors:  Amar Mirza; Morad Mustafa; Eric Talevich; Natarajan Kannan
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

Review 7.  HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.

Authors:  Ralf Landgraf
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

8.  Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis.

Authors:  Richard A Stein; James V Staros
Journal:  BMC Evol Biol       Date:  2006-10-06       Impact factor: 3.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.